Johnson & Johnson's Q3 2012 earnings call highlighted solid financial results, with sales growth slightly exceeding analyst expectations and an improved outlook for the year. Strong performance in the pharmaceutical segment, successful new product launches, and positive signs in global markets suggest increased investor confidence. Therefore, the stock price is likely to experience a positive impact in the short term.

[1]